Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients

• Published in: Cardiovascular and interventional radiology Vol. 41; no. 5; pp. 744 - 752
• Main Authors: Reimer, P., Virarkar, M. K., Binnenhei, M., Justinger, M., Schön, M. R., Tatsch, K.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2018; Springer Nature B.V
• Subjects: Aged; Bile Duct Neoplasms - diagnostic imaging; Bile Duct Neoplasms - radiotherapy; Bile Ducts, Intrahepatic - diagnostic imaging; Brachytherapy - methods; Cardiology; Cholangiocarcinoma; Cholangiocarcinoma - diagnostic imaging; Cholangiocarcinoma - radiotherapy; Clinical Investigation; Criteria; Data processing; Female; Humans; Imaging; Lobes; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; NEOPLASMS; Nuclear Medicine; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; Positron Emission Tomography Computed Tomography; Prognosis; RADIOEMBOLIZATION; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; Retrospective Studies; Solid tumors; Survival; Survival Analysis; Therapy; Treatment Outcome; Tumors; Ultrasound; Yttrium; YTTRIUM 90; Yttrium Radioisotopes - therapeutic use; Tumor burden; Yttrium-90 radioembolization; Overall survival; Intrahepatic cholangiocarcinoma
• ISSN: 0174-1551; 1432-086X
• DOI: 10.1007/s00270-017-1871-2

Introduction To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy. Materials and Methods Between 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Result The overall median survival was 15 months. Survival was significantly ( p  = 0.009) prolonged in patients with tumor burden of ≤ 25% ( n  = 8, OS 37.5 months) versus those with a tumor burden of 25–50% ( n  = 13, OS 15 months). The other variables: tumor morphology (infiltrative vs. peripheral), tumor distribution (solitary vs. multifocal), lobes involved (unilobar vs. bilobar), FDG PET status (FDG avid vs. non-avid), RE treatment sessions (1 session vs. 2 sessions), metastases (metastasis vs. no metastasis) and RECIST criteria, had no significant impact on survival. Conclusion Tumor burden represents a key prognostic factor of survival in therapy-naïve patients with unresectable ICC treated with Y-90 RE therapy only.